Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07010146 · ClinicalTrials.gov registry record · Phase 2
Role of Estrogen on Skeletal Outcomes in FHA
A Phase 2 study of Bone Density and Bone Strength, sponsored by University of Virginia.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 2
- Study locations
NCT07010146 is a Phase 2 study of Bone Density and Bone Strength that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 150 participants, below the 3,746-participant average among 7 other Bone Density trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT07010146, a Phase 2 study of Bone Density and Bone Strength, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to assess whether the natural form of estrogen (17-beta estradiol) given as a patch so that it is absorbed through your skin, is better at improving bone strength over 1 year than natural estrogen (17-beta estradiol) taken by mouth, or a synthetic form oestrogen (ethinyl estradiol) given as a patch that also provides birth control. Participants will: Take estrogen for 1 year either (i) in its natural form as a patch twice a week (and progesterone by mouth for 12 days of each month), or (ii) in its natural form as a pill daily (and progesterone by mouth for 12 days of each month), or (iii) in a synthetic form as a birth control patch weekly for 3 weeks with 1 week off the patch. You will not be able to choose which form of estrogen you will receive as this will be assigned to you based on a pre-existing randomization sequence (like the flip of a coin) Take provided calcium and vitamin D supplements Attend 4 study visits over 12 months with two at the beginning and then every 6 months that include: History and Physical Exams Lab Work Imaging studies Questionnaires Dietary recalls
Conditions Studied
Interventions
- DRUG transdermal 17β-E2 with cyclic progestin
- DRUG oral 17β-E2 with cyclic progestin
- DRUG transdermal EE+LNG
Study Locations (2)
Virginia
- University of Virginia Medical Center - Charlottesville
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-07-01 |
| Est. Completion | 2030-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07010146
The ClinicalTrials.gov registry entry for NCT07010146 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,746-participant average among 7 other Bone Density trials with a reported enrollment target (96% lower). The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Bone Density appearing as the primary indexed condition, and to 3 interventions - of which transdermal 17β-E2 with cyclic progestin is the first listed.
NCT07010146 reports 2 study locations spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT07010146 about?
NCT07010146 is a clinical study titled "Role of Estrogen on Skeletal Outcomes in FHA". The purpose of this study is to assess whether the natural form of estrogen (17-beta estradiol) given as a patch so that it is absorbed through your skin, is better at improving bone strength over 1 year than natural estrogen (17-beta estradiol) taken by mouth, or a synthetic form oestrogen (ethinyl...
What is the current status of trial NCT07010146?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2025-07-01. Estimated completion is 2030-07-01.
What conditions does trial NCT07010146 study?
This clinical trial studies the following conditions: Bone Density, Bone Strength, FHA (Functional Hypothalamic Amenorrhea).
What interventions are being tested in trial NCT07010146?
The interventions under investigation include: transdermal 17β-E2 with cyclic progestin (DRUG), oral 17β-E2 with cyclic progestin (DRUG), transdermal EE+LNG (DRUG).
Who is sponsoring clinical trial NCT07010146?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07010146 being conducted?
This trial has 2 study locations across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bone Density
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metabolic Health, Bones and Nuts During Weight Loss in Adults
RECRUITING · NA
-
Bone Metabolism in 12-21 Year Olds Undergoing GLP-1 Receptor Agonist Therapy
RECRUITING
-
VITamin D and OmegA-3 TriaL: Interrelationship of Vitamin D and Vitamin K on Bone (VITAL)
ACTIVE NOT RECRUITING · NA
-
Food Trial to Evaluate the Kinetics of the Medical Foods SBD111 and SBD121 Persistence in Healthy Adults
ACTIVE NOT RECRUITING · NA
-
Low Energy Availability, Menstrual Irregularity, and Low Bone Mass
COMPLETED
-
The Effect of Weight Loss and Dietary Protein Intake on Bone
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.